



What's Next in Biotech: The Future of Biopharma Capital Markets and M&A: Trends, Risks, and Opportunities

Events

June 9, 2026, 11:00 AM - 12:00 PM

Speaker: Timothy H. Ehrlich

In this third installment of the series, Tim Ehrlich, chair of Gunderson Dettmer's Life Sciences Group, interviewed Jefferies vice chairman of Global Healthcare Investment Banking Phil Ross about how the post-2019–2021 capital formation boom reshaped the biotech landscape and what emerging growth companies should expect from the next phase of the market cycle.

They discussed why the last several years have been challenging for early-stage and preclinical biotechs, how shifting interest rates and capital rotation affected access to public and private funding, and what lessons management teams and investors learned about timing IPOs, follow-on financings, and productivity milestones.

The conversation also looks forward to where capital is flowing now, how strategic M&A fits into companies' funding and exit strategies, and how CEOs, CFOs, and COOs can position their platforms to seize new opportunities and manage risk as we head into the second half of 2026.

Event Information

Related People



Timothy H. Ehrlich
PARTNER
P +1 617 648 9399

Featured Insights

CLIENT NEWS

Lexful Closes \$7 Million Seed Financing

FIRM NEWS

Chambers USA 2026 Guide Recognizes Multiple Gunderson Dettmer Practice Areas and Partners

CLIENT NEWS

Gunderson Dettmer Advises Aeva on \$115 Million Follow-On Offering

CLIENT NEWS

Hi Ventures Leads Trinio's \$6.4 Million Seed Financing

CLIENT NEWS

Cloud9 Leads Uncover's R\$80 Million Series A

CLIENT NEWS

Findigs Raises \$32 Million Series C

CLIENT NEWS

Novellia Secures \$18 Million Series A

PUBLIC VENTURES

'Dramatic Overreach' of Authority: SEC Proposes to Rescind Climate Disclosure Rules

FIRM NEWS

Gunderson Dettmer Commemorates 2026 Pride Month - For All of Us

CLIENT NEWS

Veritas Aortic Solutions Announces \$12 Million Seed Financing

FIRM NEWS

Gunderson Dettmer Wins 2026 China Business Law Award for Leadership in Venture Capital and Private Equity

CLIENT NEWS

Gunderson Dettmer Represents the Lead Investors in Anthropic's \$65 Billion Series H